RPRX Return on Tangible Equity | Royalty Pharma plc

Royalty Pharma plc (RPRX) Return on Tangible Equity

2026-06-30: Return Tang Equity 9.20%.
2026-03-31: Return Tang Equity 9.20%.
2025-12-31: Return Tang Equity 8.80%.
2025-09-30: Return Tang Equity 8.83%.

Complete source-backed return tang equity history.

Available history: 2018-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical Return Tang Equity

Date	Return Tang Equity
2026-06-30	9.20%
2026-03-31	9.20%
2025-12-31	8.80%
2025-09-30	8.83%
2025-06-30	11.95%
2025-03-31	11.18%
2024-12-31	8.31%
2024-09-30	11.16%
2024-06-30	6.90%
2024-03-31	8.10%
2023-12-31	11.25%
2023-09-30	1.92%
2023-06-30	2.60%
2023-03-31	3.38%
2022-12-31	0.45%
2022-09-30	4.87%
2022-06-30	4.48%
2022-03-31	5.94%
2021-12-31	6.05%
2021-09-30	7.55%
2021-06-30	9.35%
2021-03-31	9.91%
2020-12-31	14.39%
2020-09-30	13.52%
2020-06-30	26.18%
2020-03-31	28.86%

Annual Return Tang Equity

Date	Return Tang Equity
2025-12-31	8.77%
2024-12-31	8.31%
2023-12-31	11.25%
2022-12-31	0.45%
2021-12-31	6.05%
2020-12-31	9.88%
2019-12-31	38.57%
2018-12-31	30.27%

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64
Viatris Inc (VTRS)	United States	$20.008B	-0.00
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
INSMED Inc (INSM)	United States	$26.566B	-26.60
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
Jazz Pharmaceuticals plc (JAZZ)		$15.333B	16.07
Summit Therapeutics Inc. (SMMT)	United States	$13.071B	-13.21
BridgeBio Pharma, Inc. (BBIO)	United States	$12.947B	-20.72
CORCEPT THERAPEUTICS INC (CORT)	United States	$12.804B	169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)	United States	$11.879B	151.80